Mariagnese Barbera, Jenni Lehtisalo, Dinithi Perera, Malin Aspö, Mary Cross, Celeste A De Jager Loots, Emanuela Falaschetti, Naomi Friel, José A Luchsinger, Hanna Malmberg Gavelin, Markku Peltonen, Geraint Price, Anna Stigsdotter Neely, Charlotta Thunborg, Jaakko Tuomilehto, Francesca Mangialasche, Lefkos Middleton, Tiia Ngandu, Alina Solomon, Miia Kivipelto
BACKGROUND: Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in view of the well-established link between type 2 diabetes (T2D) and Alzheimer's Disease and emerging evidence of its potential neuro-protective effects (e.g. vascular, metabolic, anti-senescence). MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60-79 years) at increased risk of dementia...
January 31, 2024: Alzheimer's Research & Therapy